Page last updated: 2024-12-06

panaxadiol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Panaxadiol is a triterpene saponin found in various plants of the genus *Panax*, most notably ginseng (*Panax ginseng*). It is a key component of ginsenosides, which are believed to be responsible for many of ginseng's purported medicinal properties. Panaxadiol is known for its diverse biological activities, including:

* **Antioxidant activity:** Panaxadiol has been shown to scavenge free radicals and protect cells from oxidative damage.
* **Anti-inflammatory effects:** Studies suggest that panaxadiol can reduce inflammation by inhibiting the production of pro-inflammatory cytokines.
* **Neuroprotective properties:** Panaxadiol may protect nerve cells from damage and promote neuronal survival.
* **Cardiovascular effects:** Research indicates that panaxadiol might have beneficial effects on blood pressure and cholesterol levels.
* **Anti-cancer activity:** Panaxadiol has been studied for its potential to inhibit the growth and spread of cancer cells in various types of cancer.

Panaxadiol's importance stems from its presence in ginseng, a herb with a long history of use in traditional medicine. Researchers are interested in studying panaxadiol to better understand its mechanisms of action and explore its potential therapeutic applications. Its diverse biological activities and potential health benefits make it a promising candidate for the development of new drugs and supplements.'

panaxadiol: a protopanaxadiol with the side chain cyclized into a pyran which is an artifact of acidic hydrolysis; RN refers to (3 beta,12 beta,20R)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID73498
CHEMBL ID491655
CHEBI ID192043
SCHEMBL ID4401646
MeSH IDM0045680

Synonyms (23)

Synonym
panaxadiol
20(r)-panaxadiol
CHEMBL491655
(3s,5r,8r,9r,10r,12r,13r,14r,17s)-4,4,8,10,14-pentamethyl-17-[(2r)-2,6,6-trimethyloxan-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthrene-3,12-diol
CHEBI:192043
S3845
unii-f84blm3l74
f84blm3l74 ,
(3beta,12beta,20r)-20,25-epoxydammarane-3,12-diol
nsc 308879
CS-3846
SCHEMBL4401646
Q-100239
HY-N0596
AKOS025402314
AC-8022
bdbm50479948
mfcd00210540
DTXSID10941430
MS-28462
dammarane-3,12-diol, 20,25-epoxy-, (3beta,12beta,20r)-
88K ,
P2811

Research Excerpts

Overview

Panaxadiol is a triterpenoid sapogenin monomeric compound found in the roots of Panax ginseng. It has a variety of biological activities such as neuroprotective and anti-tumour functions.

ExcerptReferenceRelevance
"Panaxadiol is a triterpenoid sapogenin monomer found in the roots of Panax ginseng C.A.Mey."( Panaxadiol inhibits IL-1β secretion by suppressing zinc finger protein 91-regulated activation of non-canonical caspase-8 inflammasome and MAPKs in macrophages.
Jin, HL; Jin, X; Lee, JJ; Li, MY; Ma, J; Wang, JY; Xing, Y; Zhang, ZH; Zhong, Y; Zuo, HX, 2022
)
2.89
"Panaxadiol saponin (PND) is a latent targeted drug for the treatment of aplastic anemia (AA). "( Panaxadiol saponin ameliorates ferroptosis in iron-overload aplastic anemia mice and Meg-01 cells by activating Nrf2/HO-1 and PI3K/AKT/mTOR signaling pathway.
Gao, R; Lan, J; Liu, W; Mi, A; Shen, F; Tan, Z; Wang, B; Yu, X; Zhao, Y, 2023
)
3.8
"Panaxadiol is a triterpenoid sapogenin monomeric compound found in the roots of Panax ginseng and has a variety of biological activities such as neuroprotective and anti-tumour functions. "( Panaxadiol inhibits programmed cell death-ligand 1 expression and tumour proliferation via hypoxia-inducible factor (HIF)-1α and STAT3 in human colon cancer cells.
Jiang, CG; Jin, CH; Jin, HL; Jin, X; Li, MY; Ma, J; Piao, LX; Ri, M; Wang, JY; Wang, Z; Xing, Y; Xu, GH; Zhang, ZH; Zuo, HX, 2020
)
3.44
"Panaxadiol is a dammarane-type ginsenoside having high ginseng content. "( Esterified Derivatives of Panaxadiol and Their Inhibitory Effect on HL-60, THP-1, and PC-3 Cell Lines.
Ding, M; He, C; Lin, Z; Wang, Z; Zhao, Y, 2019
)
2.26
"Panaxadiol is a novel antitumor agent extracted from the Chinese medical herb Panax ginseng. "( An UFLC-MS/MS method for quantification of panaxadiol in rat plasma and its application to a pharmacokinetic study.
Xiaojun, C; Yiping, R; Yu, P; Yuping, X; Zheng, X, 2013
)
2.1
"Panaxadiol is a purified sapogenin of ginseng saponins that exhibits anticancer activity. "( Caspase-mediated pro-apoptotic interaction of panaxadiol and irinotecan in human colorectal cancer cells.
Calway, T; Du, GJ; Du, W; He, TC; Somogyi, J; Wang, CZ; Wen, XD; Yuan, CS; Zhang, ZY, 2012
)
2.08
"Panaxadiol (PD) is a purified sapogenin of ginseng saponins, which exhibits anticancer activity. "( The synergistic apoptotic interaction of panaxadiol and epigallocatechin gallate in human colorectal cancer cells.
Calway, T; Du, GJ; Du, W; He, TC; Qi, LW; Wang, CZ; Yuan, CS; Zhang, ZY, 2013
)
2.1

Pharmacokinetics

ExcerptReferenceRelevance
" The method was fully validated and successfully applied to the pharmacokinetic study of a single dose of panaxadiol."( An UFLC-MS/MS method for quantification of panaxadiol in rat plasma and its application to a pharmacokinetic study.
Xiaojun, C; Yiping, R; Yu, P; Yuping, X; Zheng, X, 2013
)
0.87

Bioavailability

ExcerptReferenceRelevance
" The absolute bioavailability was 12."( An UFLC-MS/MS method for quantification of panaxadiol in rat plasma and its application to a pharmacokinetic study.
Xiaojun, C; Yiping, R; Yu, P; Yuping, X; Zheng, X, 2013
)
0.65
" However, the low membrane permeability and the gastrointestinal tract influence seriously limit the absorption and bioavailability of ginsenosides."( Dammarane-type leads panaxadiol and protopanaxadiol for drug discovery: Biological activity and structural modification.
Cao, H; Gao, X; Hu, X; Hua, H; Li, D; Li, H; Li, Z; Liu, W; Wang, M; Xu, F, 2020
)
0.88
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
triterpenoid saponinA terpene glycoside in which the terpene moiety is a triterpenoid.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Hypoxia-inducible factor 1-alphaHomo sapiens (human)IC50 (µMol)9.10000.00072.46529.2100AID1699966
Protease Human immunodeficiency virus 1IC50 (µMol)217.10000.00000.81769.8500AID415648
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (84)

Processvia Protein(s)Taxonomy
positive regulation of chemokine-mediated signaling pathwayHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of signaling receptor activityHypoxia-inducible factor 1-alphaHomo sapiens (human)
response to hypoxiaHypoxia-inducible factor 1-alphaHomo sapiens (human)
regulation of DNA-templated transcriptionHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIHypoxia-inducible factor 1-alphaHomo sapiens (human)
response to reactive oxygen speciesHypoxia-inducible factor 1-alphaHomo sapiens (human)
angiogenesisHypoxia-inducible factor 1-alphaHomo sapiens (human)
response to hypoxiaHypoxia-inducible factor 1-alphaHomo sapiens (human)
intracellular glucose homeostasisHypoxia-inducible factor 1-alphaHomo sapiens (human)
neural crest cell migrationHypoxia-inducible factor 1-alphaHomo sapiens (human)
epithelial to mesenchymal transitionHypoxia-inducible factor 1-alphaHomo sapiens (human)
embryonic placenta developmentHypoxia-inducible factor 1-alphaHomo sapiens (human)
B-1 B cell homeostasisHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of endothelial cell proliferationHypoxia-inducible factor 1-alphaHomo sapiens (human)
heart loopingHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of neuroblast proliferationHypoxia-inducible factor 1-alphaHomo sapiens (human)
chondrocyte differentiationHypoxia-inducible factor 1-alphaHomo sapiens (human)
glandular epithelial cell maturationHypoxia-inducible factor 1-alphaHomo sapiens (human)
connective tissue replacement involved in inflammatory response wound healingHypoxia-inducible factor 1-alphaHomo sapiens (human)
outflow tract morphogenesisHypoxia-inducible factor 1-alphaHomo sapiens (human)
cardiac ventricle morphogenesisHypoxia-inducible factor 1-alphaHomo sapiens (human)
lactate metabolic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
regulation of glycolytic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
regulation of DNA-templated transcriptionHypoxia-inducible factor 1-alphaHomo sapiens (human)
intracellular iron ion homeostasisHypoxia-inducible factor 1-alphaHomo sapiens (human)
signal transductionHypoxia-inducible factor 1-alphaHomo sapiens (human)
neuroblast proliferationHypoxia-inducible factor 1-alphaHomo sapiens (human)
lactationHypoxia-inducible factor 1-alphaHomo sapiens (human)
visual learningHypoxia-inducible factor 1-alphaHomo sapiens (human)
response to iron ionHypoxia-inducible factor 1-alphaHomo sapiens (human)
regulation of gene expressionHypoxia-inducible factor 1-alphaHomo sapiens (human)
vascular endothelial growth factor productionHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of vascular endothelial growth factor productionHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of gene expressionHypoxia-inducible factor 1-alphaHomo sapiens (human)
negative regulation of gene expressionHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of epithelial cell migrationHypoxia-inducible factor 1-alphaHomo sapiens (human)
response to muscle activityHypoxia-inducible factor 1-alphaHomo sapiens (human)
axonal transport of mitochondrionHypoxia-inducible factor 1-alphaHomo sapiens (human)
neural fold elevation formationHypoxia-inducible factor 1-alphaHomo sapiens (human)
cerebral cortex developmentHypoxia-inducible factor 1-alphaHomo sapiens (human)
bone mineralizationHypoxia-inducible factor 1-alphaHomo sapiens (human)
negative regulation of bone mineralizationHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathwayHypoxia-inducible factor 1-alphaHomo sapiens (human)
TOR signalingHypoxia-inducible factor 1-alphaHomo sapiens (human)
negative regulation of TOR signalingHypoxia-inducible factor 1-alphaHomo sapiens (human)
intracellular oxygen homeostasisHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of chemokine productionHypoxia-inducible factor 1-alphaHomo sapiens (human)
regulation of transforming growth factor beta2 productionHypoxia-inducible factor 1-alphaHomo sapiens (human)
collagen metabolic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
cellular response to oxidative stressHypoxia-inducible factor 1-alphaHomo sapiens (human)
embryonic hemopoiesisHypoxia-inducible factor 1-alphaHomo sapiens (human)
insulin secretion involved in cellular response to glucose stimulusHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of insulin secretion involved in cellular response to glucose stimulusHypoxia-inducible factor 1-alphaHomo sapiens (human)
hemoglobin biosynthetic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of blood vessel endothelial cell migrationHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of erythrocyte differentiationHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of angiogenesisHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of DNA-templated transcriptionHypoxia-inducible factor 1-alphaHomo sapiens (human)
negative regulation of growthHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIHypoxia-inducible factor 1-alphaHomo sapiens (human)
muscle cell cellular homeostasisHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of hormone biosynthetic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
digestive tract morphogenesisHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of nitric-oxide synthase activityHypoxia-inducible factor 1-alphaHomo sapiens (human)
neuron apoptotic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
elastin metabolic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
intestinal epithelial cell maturationHypoxia-inducible factor 1-alphaHomo sapiens (human)
epithelial cell differentiation involved in mammary gland alveolus developmentHypoxia-inducible factor 1-alphaHomo sapiens (human)
iris morphogenesisHypoxia-inducible factor 1-alphaHomo sapiens (human)
retina vasculature development in camera-type eyeHypoxia-inducible factor 1-alphaHomo sapiens (human)
negative regulation of thymocyte apoptotic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
cellular response to interleukin-1Hypoxia-inducible factor 1-alphaHomo sapiens (human)
cellular response to hypoxiaHypoxia-inducible factor 1-alphaHomo sapiens (human)
dopaminergic neuron differentiationHypoxia-inducible factor 1-alphaHomo sapiens (human)
mesenchymal cell apoptotic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
hypoxia-inducible factor-1alpha signaling pathwayHypoxia-inducible factor 1-alphaHomo sapiens (human)
cellular response to virusHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of cytokine production involved in inflammatory responseHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of mitophagyHypoxia-inducible factor 1-alphaHomo sapiens (human)
negative regulation of miRNA transcriptionHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of miRNA transcriptionHypoxia-inducible factor 1-alphaHomo sapiens (human)
negative regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathwayHypoxia-inducible factor 1-alphaHomo sapiens (human)
regulation of aerobic respirationHypoxia-inducible factor 1-alphaHomo sapiens (human)
negative regulation of reactive oxygen species metabolic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
regulation of protein neddylationHypoxia-inducible factor 1-alphaHomo sapiens (human)
negative regulation of mesenchymal cell apoptotic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
regulation of transcription by RNA polymerase IIHypoxia-inducible factor 1-alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (23)

Processvia Protein(s)Taxonomy
DNA-binding transcription factor activity, RNA polymerase II-specificHypoxia-inducible factor 1-alphaHomo sapiens (human)
sequence-specific DNA bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificHypoxia-inducible factor 1-alphaHomo sapiens (human)
cis-regulatory region sequence-specific DNA bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
DNA-binding transcription activator activityHypoxia-inducible factor 1-alphaHomo sapiens (human)
DNA-binding transcription repressor activityHypoxia-inducible factor 1-alphaHomo sapiens (human)
transcription coactivator bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificHypoxia-inducible factor 1-alphaHomo sapiens (human)
p53 bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
DNA-binding transcription factor activityHypoxia-inducible factor 1-alphaHomo sapiens (human)
protein bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
nuclear receptor bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
enzyme bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
protein kinase bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
protein domain specific bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
ubiquitin protein ligase bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
histone deacetylase bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
protein heterodimerization activityHypoxia-inducible factor 1-alphaHomo sapiens (human)
Hsp90 protein bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
E-box bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
transcription regulator activator activityHypoxia-inducible factor 1-alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (12)

Processvia Protein(s)Taxonomy
nucleusHypoxia-inducible factor 1-alphaHomo sapiens (human)
nucleoplasmHypoxia-inducible factor 1-alphaHomo sapiens (human)
cytoplasmHypoxia-inducible factor 1-alphaHomo sapiens (human)
cytosolHypoxia-inducible factor 1-alphaHomo sapiens (human)
nuclear bodyHypoxia-inducible factor 1-alphaHomo sapiens (human)
nuclear speckHypoxia-inducible factor 1-alphaHomo sapiens (human)
motile ciliumHypoxia-inducible factor 1-alphaHomo sapiens (human)
axon cytoplasmHypoxia-inducible factor 1-alphaHomo sapiens (human)
chromatinHypoxia-inducible factor 1-alphaHomo sapiens (human)
euchromatinHypoxia-inducible factor 1-alphaHomo sapiens (human)
protein-containing complexHypoxia-inducible factor 1-alphaHomo sapiens (human)
RNA polymerase II transcription regulator complexHypoxia-inducible factor 1-alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (28)

Assay IDTitleYearJournalArticle
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID599443Cytotoxicity against human ES2 cells assessed as cell viability at 50 uM after 48 hrs by MTT assay2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Synthesis and anti-tumor evaluation of panaxadiol derivatives.
AID415648Inhibition of HIV1 protease by HPLC method2009Bioorganic & medicinal chemistry, Apr-15, Volume: 17, Issue:8
Synthesis of dammarane-type triterpene derivatives and their ability to inhibit HIV and HCV proteases.
AID599449Cytotoxicity against human A549 cells assessed as cell viability at 100 uM after 48 hrs by MTT assay2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Synthesis and anti-tumor evaluation of panaxadiol derivatives.
AID1674939Activation of human CK-MM assessed as increase in enzyme activity at 40 uM relative to control2020Bioorganic & medicinal chemistry letters, 09-01, Volume: 30, Issue:17
Structure-activity relationship analysis of dammarane-type natural products as muscle-type creatine kinase activators.
AID599447Cytotoxicity against human HepG2 cells assessed as cell viability at 50 uM after 48 hrs by MTT assay2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Synthesis and anti-tumor evaluation of panaxadiol derivatives.
AID415649Inhibition of HCV protease by fluorometric method2009Bioorganic & medicinal chemistry, Apr-15, Volume: 17, Issue:8
Synthesis of dammarane-type triterpene derivatives and their ability to inhibit HIV and HCV proteases.
AID599439Cytotoxicity against human U2OS cells after 48 hrs by MTT assay2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Synthesis and anti-tumor evaluation of panaxadiol derivatives.
AID599441Cytotoxicity against human A549 cells after 48 hrs by MTT assay2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Synthesis and anti-tumor evaluation of panaxadiol derivatives.
AID599444Cytotoxicity against human U2OS cells assessed as cell viability at 25 uM after 48 hrs by MTT assay2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Synthesis and anti-tumor evaluation of panaxadiol derivatives.
AID599446Cytotoxicity against human HepG2 cells assessed as cell viability at 25 uM after 48 hrs by MTT assay2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Synthesis and anti-tumor evaluation of panaxadiol derivatives.
AID1571184Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay2018MedChemComm, Nov-01, Volume: 9, Issue:11
Synthesis, characterization and cytotoxic activity evaluation of ginsengdiol oxidation and nitrogen hybrid derivatives.
AID1699967Cytotoxicity against human Hep3B cells assessed as reduction in cell viability incubated for 24 hrs under normaxic condition by MTT assay2020Bioorganic & medicinal chemistry letters, 12-15, Volume: 30, Issue:24
Synthesis and evaluation of HIF-1α inhibitory activities of novel panaxadiol derivatives.
AID599438Cytotoxicity against human ES2 cells after 48 hrs by MTT assay2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Synthesis and anti-tumor evaluation of panaxadiol derivatives.
AID599448Cytotoxicity against human A549 cells assessed as cell viability at 50 uM after 48 hrs by MTT assay2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Synthesis and anti-tumor evaluation of panaxadiol derivatives.
AID1674942Binding affinity to recombinant human His-tagged CK-MM at 20 uM by Biolayer Interferometry analysis2020Bioorganic & medicinal chemistry letters, 09-01, Volume: 30, Issue:17
Structure-activity relationship analysis of dammarane-type natural products as muscle-type creatine kinase activators.
AID1571182Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay2018MedChemComm, Nov-01, Volume: 9, Issue:11
Synthesis, characterization and cytotoxic activity evaluation of ginsengdiol oxidation and nitrogen hybrid derivatives.
AID1571183Cytotoxicity against human 8901 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay2018MedChemComm, Nov-01, Volume: 9, Issue:11
Synthesis, characterization and cytotoxic activity evaluation of ginsengdiol oxidation and nitrogen hybrid derivatives.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID599442Cytotoxicity against human ES2 cells assessed as cell viability at 25 uM after 48 hrs by MTT assay2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Synthesis and anti-tumor evaluation of panaxadiol derivatives.
AID1571181Cytotoxicity against human U87 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay2018MedChemComm, Nov-01, Volume: 9, Issue:11
Synthesis, characterization and cytotoxic activity evaluation of ginsengdiol oxidation and nitrogen hybrid derivatives.
AID1699966Inhibition of hypoxia-induced HIF1alpha transcriptional activity in human Hep3B cells co-transfected with luciferase reporter plasmid containing six copies of HREs and pRL-CMV vector assessed as reduction in luciferase activity incubated for 24 hrs under 2020Bioorganic & medicinal chemistry letters, 12-15, Volume: 30, Issue:24
Synthesis and evaluation of HIF-1α inhibitory activities of novel panaxadiol derivatives.
AID599445Cytotoxicity against human U2OS cells assessed as cell viability at 50 uM after 48 hrs by MTT assay2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Synthesis and anti-tumor evaluation of panaxadiol derivatives.
AID1674940Activation of human CK-MM assessed as increase in enzyme activity at 80 uM relative to control2020Bioorganic & medicinal chemistry letters, 09-01, Volume: 30, Issue:17
Structure-activity relationship analysis of dammarane-type natural products as muscle-type creatine kinase activators.
AID1571186Cytotoxicity against human IOSE-144 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay2018MedChemComm, Nov-01, Volume: 9, Issue:11
Synthesis, characterization and cytotoxic activity evaluation of ginsengdiol oxidation and nitrogen hybrid derivatives.
AID1571185Cytotoxicity against human HeLa cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay2018MedChemComm, Nov-01, Volume: 9, Issue:11
Synthesis, characterization and cytotoxic activity evaluation of ginsengdiol oxidation and nitrogen hybrid derivatives.
AID599440Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Synthesis and anti-tumor evaluation of panaxadiol derivatives.
AID1674938Activation of human CK-MM assessed as increase in enzyme activity at 20 uM relative to control2020Bioorganic & medicinal chemistry letters, 09-01, Volume: 30, Issue:17
Structure-activity relationship analysis of dammarane-type natural products as muscle-type creatine kinase activators.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (80)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (8.75)18.7374
1990's15 (18.75)18.2507
2000's10 (12.50)29.6817
2010's27 (33.75)24.3611
2020's21 (26.25)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 26.38

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index26.38 (24.57)
Research Supply Index4.41 (2.92)
Research Growth Index5.00 (4.65)
Search Engine Demand Index31.58 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (26.38)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (2.47%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other79 (97.53%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]